Avana Health Secures $2.8M

Avana Health, a women’s health company focused on treating areas of unmet need, has announced it has secured $2.8 million in new investment capital.

This funding round marks a significant step for the company as it advances its mission to address critical health challenges affecting women globally.

The capital infusion will support the continued development and expansion of its innovative medical solutions.

The company has developed a proprietary drug + device system designed to treat two major conditions: Abnormal Uterine Bleeding (AUB) and Postpartum Hemorrhage (PPH).

AUB is a widespread issue, responsible for one-third of all gynecology visits, while PPH remains the leading cause of maternal death globally.

Avana Health's system aims to provide an effective and accessible treatment option for these conditions.

Avana Health's treatment is engineered for efficiency and broad applicability.

It is designed to work in less than three minutes, making it a rapid intervention tool.

Furthermore, its design allows for use by a wide range of healthcare practitioners, increasing its potential reach.

A key aspect of the company's strategy is to ensure the treatment is low cost, thereby making it accessible to patients in low and middle-income countries (LMICs) where resources may be limited and the need is often greatest.

The $2.8 million in secured funding will be strategically deployed to accelerate Avana Health's growth initiatives.

This includes advancing the development of its drug + device system through clinical stages and navigating regulatory pathways to bring its solution to market.

The investment underscores confidence in Avana Health's approach to addressing significant gaps in women's healthcare.

Looking ahead, Avana Health plans to leverage this investment to expand its operational capabilities and further its commitment to improving maternal and gynecological health outcomes worldwide.

The company is focused on bringing its accessible and rapid treatment system to patients who need it most, aiming for a substantial impact on global health.